Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Signaling networks assembled by oncogenic EGFR and c-Met.

Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7. doi: 10.1073/pnas.0707270105.

2.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Review.

PMID:
24355409
3.
4.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.

Remon J, Morán T, Majem M, Reguart N, Dalmau E, Márquez-Medina D, Lianes P.

Cancer Treat Rev. 2014 Feb;40(1):93-101. doi: 10.1016/j.ctrv.2013.06.002. Review.

PMID:
23829935
5.
6.

Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Chang K, Karnad A, Zhao S, Freeman JW.

Oncotarget. 2015 Feb 28;6(6):3507-18. Review.

Items per page

Supplemental Content

Support Center